Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2019 07:00 ET | Source: Summit Therapeutics plc

Increased BARDA Award and Option Exercise

Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract...